Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

What's the purpose of this trial?

This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.

This trial is currently open and accepting patients.


You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

  1. Signed informed consent
  2. 18 years of age or older
  3. Multiple myeloma (MM) diagnosed according to IMWG criteria
  4. Measurable disease (this is defined differently in different arms)
  5. Multiple myeloma relapsed or refractory to treatment (this is defined differently in different arms)
  6. Meet certain clinical laboratory criteria
  7. ECOG performance status ≤2
  8. Life expectancy of at least 3 months
  9. For women of childbearing potential, a negative serum or urine pregnancy test prior to study treatment.
  10. For women who are not postmenopausal (12 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two methods of contraception one of which must be highly effective
  11. For men: agreement to use a barrier method of contraception for 1 month before start of study treatment, during the treatment period and for 6 months after the last dose of study treatment.

Exclusion Criteria:

  1. Failure to have fully recovered (i.e. ≤ Grade 1 toxicity) from the effects of prior chemotherapy (except for alopecia)
  2. Active graft versus host disease
  3. Treatment with any of the following:
    1. Cytotoxic chemotherapy within 3 weeks prior to the initiation of study treatment
    2. Proteasome inhibitors, Imids, or monoclonal antibodies within 2 weeks prior to the initiation of study treatment
    3. Experimental therapy within 4 weeks or 5 half-lives, whichever is shorter
    4. Systemic corticosteroids >=10 mg prednisone or equivalent within 7 days prior to the initiation of study treatment
    5. Radiotherapy within 7 days prior to initiating study treatment
    6. Plasmapheresis within 4 weeks prior to the initiation of study treatment
    7. Tasquinimod at any time
  4. Known central nervous system involvement by myeloma
  5. Diagnosis of smoldering multiple myeloma
  6. Diagnosis of POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  7. Active plasma cell leukemia
  8. Symptomatic primary (AL) amyloidosis
  9. Diagnosis of myelodysplastic syndrome or myeloproliferative syndrome
  10. Active other malignancy
  11. Major surgery within 4 weeks prior to initiating study treatment
  12. Evidence of severe or currently uncontrolled cardiovascular condition
  13. Ongoing or active systemic infection that requires systemic antibiotic or parenteral anti-infective therapy
  14. Active tuberculosis, active hepatitis A, B or C virus infection, or known human immunodeficiency virus (HIV) positive
  15. History of pancreatitis
  16. History of malabsorption or other condition that would interfere with absorption of study drugs
  17. Systemic treatment within 14 days prior to the initiation of study treatment with moderate or strong inhibitor or moderate or strong inducer of cytochrome P-3A4 (CYP3A4)
  18. Need for ongoing therapy drug substances of narrow therapeutic range that are metabolized mainly by CYP3A4 (alfentanil, fentanyl, quinidine, astemizole, terfenadine, sirolimus, tacrolimus, cyclosporine, cisapride, ergotamine)
  19. Need for ongoing therapy with drug substances of narrow therapeutic range metabolized mainly by CYP1A2 (duloxetine, alosetron, theophylline, tizanidine, ondansetron)
  20. Ongoing treatment with warfarin, unless the INR is <=3.0.
  21. For subjects enrolled on the IRd combination arms, prior dose-limiting toxicity with lenalidomide or ixazomib or absolute contraindication to concomitant thrombosis prophylaxis
  22. Peripheral neuropathy grade ≥2 (NCI-CTCAE)
  23. Known hypersensitivity to tasquinimod or any excipients in the study treatments
  24. Pregnant or nursing (lactating) women
  25. Any other condition that would, in the Investigator's judgment, contraindicate subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures
  26. Prior inclusion in this study

Additional Trial Information

Phase 1

Enrollment: 34 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Pennsylvania

Abramson Cancer Center University of Pennsylvania

Philadelphia, PA

Open and Accepting

Trial Links

Read the latest news and updates on this trial.

Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message